Bioxcel therapeutics reports fourth quarter and full year 2020 financial results and provides business update

New drug application (“nda”) submitted to the u.s. food and drug administration (“fda”) for bxcl501 for the acute treatment of schizophrenia and bipolar disorder related agitation

BTAI Ratings Summary

BTAI Quant Ranking